Privacy Policy

English French Hungarian Cookie Settings Your privacy is important to X-Chem and its affiliates (hereinafter “we” and/or “us” and/or β€œX-Chem”) and we...

Blog

Does Size Matter in DEL Screening?

June 23, 2022

One of the most attractive aspects of DNA-encoded library (DEL) technology is the vast number of compounds that can be...

News

X‑Chem Announces Strategic Collaboration with Astellas Pharma Across Multiple Therapeutic Areas

March 20, 2017

WALTHAM, Mass. – March 20 2017 – X-Chem, Inc. (X-Chem), a privately held biotechnology company applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics, announced the signing of a broad drug discovery collaboration with Astellas Pharma Inc. (Astellas). The collaboration will enable the discovery of novel lead compounds for complex drug targets of interest to Astellas from X-Chem’s growing collection of DNA-encoded DEXβ„’ libraries containing over 120 billion compounds. This new partnership is X-Chem’s most expansive first-time alliance with a pharmaceutical company, and is aimed at tackling hard-to-drug targets across multiple therapeutic areas at Astellas.

Blog

Proof of Concept: DEL for PROTACs

June 15, 2021

DNA-Encoded Chemical Library Screening Is a Great Tool for Identifying Novel Binders Suitable for Bispecific Degraders The Value of DEL...